Semin Respir Crit Care Med 2019; 40(02): 194-207
DOI: 10.1055/s-0039-1683995
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pulmonary Complications of Rheumatoid Arthritis

Hamish Farquhar
1   Department of Allergy, Immunology and Rheumatology, Christchurch Hospital, Christchurch, New Zealand
,
Robert Vassallo
2   Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
,
Adrienne L. Edwards*
3   Respiratory Department, Christchurch Hospital, Christchurch, New Zealand
,
Eric L. Matteson*
1   Department of Allergy, Immunology and Rheumatology, Christchurch Hospital, Christchurch, New Zealand
4   Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Mai 2019 (online)

Abstract

Rheumatoid arthritis (RA) is a common chronic autoimmune disorder that characteristically causes joint inflammation and damage. In addition, many patients develop extraarticular manifestations which may cause significant comorbidity and premature mortality.

Some respiratory tract involvement of the upper and lower airways and parenchymal disease features are unique to RA, including cricoarytenoid arthritis and RA pulmonary nodulosis, and others, especially the interstitial parenchymal involvement, occur in many other idiopathic and autoimmune diseases. The pathophysiology of lung disease is not well understood. Rheumatoid lung disease may even predate the onset of joint disease, and could be triggered by chronic airway and alveolar epithelial injury. Chronic systemic inflammation and risk factors such as cigarette smoking, infection, host genetics, and immune dysregulation are contributors. Treatment of the respiratory disease is directed at reducing the systemic inflammation of RA. Less well understood is the management of the interstitial lung disease of RA, for which antifibrotic and immune suppressive agents may be helpful. The management of RA-related lung disease is perhaps the major remaining hurdle in reduction of the disease burden related to extraarticular manifestations of this disease.

* Both the authors contributed equally to this work.


 
  • References

  • 1 Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol 2011; 38 (06) 983-989
  • 2 Bongartz T, Nannini C, Medina-Velasquez YF. , et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62 (06) 1583-1591
  • 3 Olson AL, Swigris JJ, Sprunger DB. , et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183 (03) 372-378
  • 4 Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56 (08) 622-627
  • 5 Gabbay E, Tarala R, Will R. , et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156 (2, Pt 1): 528-535
  • 6 Gochuico BR, Avila NA, Chow CK. , et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008; 168 (02) 159-166
  • 7 Saag KG, Kolluri S, Koehnke RK. , et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39 (10) 1711-1719
  • 8 Giles JT, Danoff SK, Sokolove J. , et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis 2014; 73 (08) 1487-1494
  • 9 Gilligan DM, O'Connor CM, Ward K, Moloney D, Bresnihan B, FitzGerald MX. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 1990; 45 (08) 591-596
  • 10 Yin Y, Liang D, Zhao L. , et al. Anti-cyclic citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis. PLoS One 2014; 9 (04) e92449
  • 11 Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med 2012; 106 (11) 1591-1599
  • 12 Bartels CM, Bell CL, Shinki K, Rosenthal A, Bridges AJ. Changing trends in serious extra-articular manifestations of rheumatoid arthritis among United State veterans over 20 years. Rheumatology (Oxford) 2010; 49 (09) 1670-1675
  • 13 Cavagna L, Monti S, Grosso V. , et al. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. BioMed Res Int 2013; 2013: 759760
  • 14 Lee HK, Kim DS, Yoo B. , et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127 (06) 2019-2027
  • 15 Zrour SH, Touzi M, Bejia I. , et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine 2005; 72 (01) 41-47
  • 16 Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4 (05) 443-448
  • 17 Jacob J, Hirani N, van Moorsel CHM. , et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53 (01) 1800869
  • 18 Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2017; 36 (04) 817-823
  • 19 Krause ML, Zamora AC, Vassallo R, Ryu JH, Matteson EL. The lung disease of rheumatoid arthritis. Curr Respir Med Rev 2015; 11 (02) 119-129
  • 20 Shidara K, Hoshi D, Inoue E. , et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 2010; 20 (03) 280-286
  • 21 Koduri G, Norton S, Young A. , et al; ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49 (08) 1483-1489
  • 22 Kelly CA, Saravanan V, Nisar M. , et al; British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 2014; 53 (09) 1676-1682
  • 23 Bernstein EJ, Barr RG, Austin JHM. , et al. Rheumatoid arthritis-associated autoantibodies and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis. Thorax 2016; 71 (12) 1082-1090
  • 24 Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997; 56 (08) 463-469
  • 25 Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore) 2013; 92 (02) 92-97
  • 26 Murphy D, Hutchinson D. Is male rheumatoid arthritis an occupational disease? A review. Open Rheumatol J 2017; 11: 88-105
  • 27 Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373 (9664): 659-672
  • 28 Solomon JJ, Chung JH, Cosgrove GP. , et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47 (02) 588-596
  • 29 Mikuls TR, Payne JB, Deane KD, Thiele GM. Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: the spark that lights the fire in rheumatoid arthritis?. J Allergy Clin Immunol 2016; 137 (01) 28-34
  • 30 Bongartz T, Cantaert T, Atkins SR. , et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (01) 70-75
  • 31 Willis VC, Demoruelle MK, Derber LA. , et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 2013; 65 (10) 2545-2554
  • 32 Quirke AM, Perry E, Cartwright A. , et al. Bronchiectasis is a model for chronic bacterial infection inducing autoimmunity in rheumatoid arthritis. Arthritis Rheumatol 2015; 67 (09) 2335-2342
  • 33 Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50 (10) 3085-3092
  • 34 Van Hove CL, Moerloose K, Maes T, Joos GF, Tournoy KG. Cigarette smoke enhances Th-2 driven airway inflammation and delays inhalational tolerance. Respir Res 2008; 9: 42
  • 35 Vassallo R, Walters PR, Lamont J, Kottom TJ, Yi ES, Limper AH. Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir Res 2010; 11: 45
  • 36 Checa M, Hagood JS, Velazquez-Cruz R. , et al. Cigarette smoke enhances the expression of profibrotic molecules in alveolar epithelial cells. PLoS One 2016; 11 (03) e0150383
  • 37 Sendo S, Saegusa J, Okano T, Takahashi S, Akashi K, Morinobu A. CD11b+Gr-1(dim) tolerogenic dendritic cell-like cells are expanded in interstitial lung disease in SKG mice. Arthritis Rheumatol 2017; 69 (12) 2314-2327
  • 38 Nguyen NT, Hanieh H, Nakahama T, Kishimoto T. The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 2013; 25 (06) 335-343
  • 39 Makrygiannakis D, Hermansson M, Ulfgren AK. , et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008; 67 (10) 1488-1492
  • 40 Lee J, Luria A, Rhodes C. , et al. Nicotine drives neutrophil extracellular traps formation and accelerates collagen-induced arthritis. Rheumatology (Oxford) 2017; 56 (04) 644-653
  • 41 Vassallo R, Luckey D, Behrens M. , et al. Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes. Clin Immunol 2014; 152 (1–2): 25-35
  • 42 Scher JU, Joshua V, Artacho A. , et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 2016; 4 (01) 60
  • 43 Mikuls TR, Payne JB, Yu F. , et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66 (05) 1090-1100
  • 44 Bidkar M, Vassallo R, Luckey D, Smart M, Mouapi K, Taneja V. Cigarette smoke induces immune responses to vimentin in both arthritis-susceptible and -resistant humanized mice. PLoS One 2016; 11 (09) e0162341
  • 45 Snir O, Rieck M, Gebe JA. , et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63 (10) 2873-2883
  • 46 Reynisdottir G, Karimi R, Joshua V. , et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 2014; 66 (01) 31-39
  • 47 Clavel C, Nogueira L, Laurent L. , et al. Induction of macrophage secretion of tumor necrosis factor α through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008; 58 (03) 678-688
  • 48 Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A. , et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5 (178) 178ra40
  • 49 Schafer MJ, White TA, Iijima K. , et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 2017; 8: 14532
  • 50 Fujii H, Shao L, Colmegna I, Goronzy JJ, Weyand CM. Telomerase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci U S A 2009; 106 (11) 4360-4365
  • 51 Juge PA, Borie R, Kannengiesser C. , et al; FREX consortium. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49 (05) 1602314
  • 52 Seibold MA, Wise AL, Speer MC. , et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364 (16) 1503-1512
  • 53 Borie R, Crestani B, Dieude P. , et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8 (08) e70621
  • 54 Johnson C, Rosen P, Lloyd T. , et al. Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respir Med 2017; 130: 52-54
  • 55 Juge PA, Lee JS, Ebstein E. , et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med 2018; 379 (23) 2209-2219
  • 56 Mangan PR, Harrington LE, O'Quinn DB. , et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441 (7090): 231-234
  • 57 Hara M, Kono H, Furuya S, Hirayama K, Tsuchiya M, Fujii H. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. J Surg Res 2013; 183 (02) 574-582
  • 58 Doyle TJ, Patel AS, Hatabu H. , et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med 2015; 191 (12) 1403-1412
  • 59 Putman RK, Hatabu H, Araki T. , et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators; COPDGene Investigators. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016; 315 (07) 672-681
  • 60 Travis WD, Costabel U, Hansell DM. , et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188 (06) 733-748
  • 61 Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest 2017; 152 (06) 1283-1295
  • 62 Hyldgaard C, Hilberg O, Pedersen AB. , et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 2017; 76 (10) 1700-1706
  • 63 Sgalla G, Larici AR, Sverzellati N. , et al. Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study. Eur Respir J 2018. doi: 10.1183/13993003.02093-2018
  • 64 Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis - focus on interstitial lung disease. Arthritis Rheumatol 2018; 70 (10) 1544-1554
  • 65 Saketkoo LA, Matteson EL, Brown KK, Seibold JR, Strand V. ; Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group. Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease. J Rheumatol 2011; 38 (07) 1514-1518
  • 66 Khanna D, Mittoo S, Aggarwal R. , et al. Connective tissue disease-associated interstitial lung diseases: report from OMERACT CTD-ILD Working Group. J Rheumatol 2015; 42 (11) 2168-2171
  • 67 Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 2001; 40 (09) 1022-1025
  • 68 Ito Y, Arita M, Kumagai S. , et al. Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol 2019; 29 (01) 98-104
  • 69 Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014; 19 (04) 493-500
  • 70 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford) 2017; 56 (03) 344-350
  • 71 Bradley B, Branley HM, Egan JJ. , et al; British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 (Suppl. 05) v1-v58
  • 72 Jani M, Dixon W, Matteson EL. Management of the patient with rheumatoid arthritis and interstitial lung disease. In: Fischer A, Lee J. , eds. Lung Disease in Rheumatoid Arthritis. New York, NY: Humana Press (Springer); 2018: 121-161
  • 73 Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol 2016; 28 (03) 236-245
  • 74 Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol 2014; 10 (12) 728-739
  • 75 Kouranos V, Miranda G, Corte TJ, Renzoni EA. New treatment paradigms for connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 2018; 24 (05) 453-460
  • 76 Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366 (21) 1968-1977
  • 77 Song JW, Lee HK, Lee CK. , et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (02) 103-112
  • 78 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis associated interstitial lung disease. Arthritis Rheumatol 2017; 69 (03) 542-549
  • 79 Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 2014; 10 (05) 284-294
  • 80 Richeldi L, du Bois RM, Raghu G. , et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2071-2082
  • 81 King Jr TE, Bradford WZ, Castro-Bernardini S. , et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2083-2092
  • 82 Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. ; IPF Consensus Working Group. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51 (05) 1800692
  • 83 ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02808871 . Accessed March 4, 2019
  • 84 Cho J, Zhou J, Lo D, Mak A, Tay SH. Palliative and end-of-life care in rheumatology: high symptom prevalence and unmet needs. Semin Arthritis Rheum 2018 (e-pub ahead of print). Doi: 10.1016/j.semarthrit.2018.10.020
  • 85 Luckett T, Phillips J, Johnson MJ. , et al. Contributions of a hand-held fan to self-management of chronic breathlessness. Eur Respir J 2017; 50 (02) 1700262
  • 86 Smallwood N, Thompson M, Warrender-Sparkes M. , et al. Integrated respiratory and palliative care may improve outcomes in advanced lung disease. ERJ Open Res 2018; 4 (01) 00102-02017
  • 87 Kreuter M, Bendstrup E, Russell AM. , et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med 2017; 5 (12) 968-980
  • 88 Courtwright AM, El-Chemaly S, Dellaripa PF, Goldberg HJ. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease. J Heart Lung Transplant 2017; 36 (07) 763-769
  • 89 Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014; 33 (05) 514-520
  • 90 Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol 1982; 11 (04) 217-224
  • 91 Talbott JA, Calkins E. Pulmonary involvement in rheumatoid Arthritis. JAMA 1964; 189 (12) 911-913
  • 92 Horler AR, Thompson M. The pleural and pulmonary complications of rheumatoid arthritis. Ann Intern Med 1959; 51 (06) 1179-1203
  • 93 Walker WC, Wright V. Rheumatoid pleuritis. Ann Rheum Dis 1967; 26 (06) 467-474
  • 94 Jurik AG, Graudal H. Pleurisy in rheumatoid arthritis. Scand J Rheumatol 1983; 12 (02) 75-80
  • 95 Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35 (06) 368-378
  • 96 Hakala M, Tiilikainen A, Hämeenkorpi R. , et al. Rheumatoid arthritis with pleural effusion includes a subgroup with autoimmune features and HLA-B8, Dw3 association. Scand J Rheumatol 1986; 15 (03) 290-296
  • 97 Allan JS, Donahue DM, Garrity JM. Rheumatoid pleural effusion in the absence of arthritic disease. Ann Thorac Surg 2005; 80 (04) 1519-1521
  • 98 Russell ML, Gladman DD, Mintz S. Rheumatoid pleural effusion: lack of response to intrapleural corticosteroid. J Rheumatol 1986; 13 (02) 412-415
  • 99 Faurschou P, Francis D, Faarup P. Thoracoscopic, histological, and clinical findings in nine case of rheumatoid pleural effusion. Thorax 1985; 40 (05) 371-375
  • 100 Shinto R, Prete P. Characteristic cytology in rheumatoid pleural effusion. Am J Med 1988; 85 (04) 587-589
  • 101 Pettersson T, Klockars M, Hellström PE. Chemical and immunological features of pleural effusions: comparison between rheumatoid arthritis and other diseases. Thorax 1982; 37 (05) 354-361
  • 102 Pereyra MF, Ferreiro L, Valdés L. Unexpandable lung. Arch Bronconeumol 2013; 49 (02) 63-69
  • 103 Jones Jr FL, Blodgett Jr RC. Empyema in rheumatoid pleuropulmonary disease. Ann Intern Med 1971; 74 (05) 665-671
  • 104 Sahn SA, Kaplan RL, Maulitz RM, Good Jr JT. Rheumatoid pleurisy. observations on the development of low pleural fluid pH and glucose level. Arch Intern Med 1980; 140 (09) 1237-1238
  • 105 Wrightson JM, Stanton AE, Maskell NA, Davies RJO, Lee YCG. Pseudochylothorax without pleural thickening: time to reconsider pathogenesis?. Chest 2009; 136 (04) 1144-1147
  • 106 Chapman PT, O'Donnell JL, Moller PW. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992; 19 (03) 478-480
  • 107 Fujita S, Mukai T, Akagi T, Morita Y. Treatment of refractory rheumatoid pleural effusion with abatacept. BMJ Case Rep 2018. Doi: 10.1136/bcr-2017-224034
  • 108 Ohtsuka K, Takeuchi K, Matsushita M, Aramaki T. A case of bilateral rheumatoid pleuritis successfully treated with tocilizumab. Mod Rheumatol 2014; 24 (06) 1001-1004
  • 109 Patil M, Dhillon SS, Attwood K, Saoud M, Alraiyes AH, Harris K. Management of benign pleural effusions using indwelling pleural catheters. Chest 2017; 151 (03) 626-635
  • 110 Cortet B, Perez T, Roux N. , et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56 (10) 596-600
  • 111 Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R. Rheumatoid pneumoconiosis (Caplan's syndrome). Eur J Intern Med 2010; 21 (03) 168-172
  • 112 Koslow M, Young JR, Yi ES. , et al. Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. Eur Radiol 2019; 29: 1684-1692
  • 113 Balkarli A, Cobankara V. Pulmonary nodulosis associated with leflunomide therapy in rheumatoid arthritis: report of four cases and review of the literature. J Clin Exp Invest 2016; 7 (01) 98-102
  • 114 Steeghs N, Huizinga TW, Dik H. Bilateral hydropneumothoraces in a patient with pulmonary rheumatoid nodules during treatment with methotrexate. Ann Rheum Dis 2005; 64 (11) 1661-1662
  • 115 Toussirot E, Berthelot JM, Pertuiset E. , et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009; 36 (11) 2421-2427
  • 116 Highton J, Hung N, Hessian P, Wilsher M. Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology (Oxford) 2007; 46 (05) 811-814
  • 117 MacMahon H, Naidich DP, Goo JM. , et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017; 284 (01) 228-243
  • 118 Glace B, Gottenberg JE, Mariette X. , et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis 2012; 71 (08) 1429-1431
  • 119 Sargin G, Senturk T. Multiple pulmonary rheumatoid nodules. Reumatologia 2015; 53 (05) 276-278
  • 120 Andres M, Vela P, Romera C. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatology (Oxford) 2012; 51 (06) 1134-1136
  • 121 Derot G, Marini-Portugal A, Maitre B, Claudepierre P. Marked regression of pulmonary rheumatoid nodules under etanercept therapy. J Rheumatol 2009; 36 (02) 437-439
  • 122 Bozbas G, Gunel C, Gurer G, Karatas R, Ermisler B. An often overlooked joint in rheumatoid arthritis: cricoarytenoid joint. Biomed Res 2017; 28 (04) 1733-1737
  • 123 Huang K, Kur J. Laryngeal stridor in rheumatoid arthritis. CMAJ 2017; 189 (38) E1213
  • 124 Fuld JP, Johnson MK, Cotton MM. , et al. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. Chest 2003; 124 (04) 1224-1231
  • 125 Nannini C, Medina-Velasquez YF, Achenbach SJ. , et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2013; 65 (08) 1243-1250
  • 126 Hassan WU, Keaney NP, Holland CD, Kelly CA. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 1994; 53 (08) 511-514
  • 127 Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care 2013; 58 (04) 694-701
  • 128 Mohd Noor N, Mohd Shahrir MS, Shahid MS, Abdul Manap R, Shahizon Azura AM, Azhar Shah S. Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease. Int J Rheum Dis 2009; 12 (02) 136-144
  • 129 De Soyza A, McDonnell MJ, Goeminne PC. , et al. Bronchiectasis rheumatoid overlap syndrome is an independent risk factor for mortality in patients with bronchiectasis: a multicenter cohort study. Chest 2017; 151 (06) 1247-1254
  • 130 Devouassoux G, Cottin V, Lioté H. , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM“O”P). Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33 (05) 1053-1061
  • 131 Lin E, Limper AH, Moua T. Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series. BMC Pulm Med 2018; 18 (01) 105
  • 132 Tashtoush B, Okafor NC, Ramirez JF, Smolley L. Follicular bronchiolitis: a literature review. J Clin Diagn Res 2015; 9 (09) OE01-OE05
  • 133 Yuksekkaya R, Celikyay F, Yilmaz A. , et al. Pulmonary involvement in rheumatoid arthritis: multidetector computed tomography findings. Acta Radiol 2013; 54 (10) 1138-1149
  • 134 Petrie JP, Caughey DE. Bilateral apical fibrobullous disease complicated by bilateral Aspergillus mycetomata in rheumatoid arthritis. N Z Med J 1983; 96 (723) 7-8
  • 135 Bégin R, Radoux V, Cantin A, Ménard HA. Stiffness of the rib cage in a subset of rheumatoid patients. Hai 1988; 166 (03) 141-148
  • 136 Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther 2014; 16 (05) 435
  • 137 Montani D, Henry J, O'Connell C. , et al. Association between rheumatoid arthritis and pulmonary hypertension: data from the French Pulmonary Hypertension Registry. Respiration 2018; 95 (04) 244-250
  • 138 Badesch DB, Raskob GE, Elliott CG. , et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137 (02) 376-387
  • 139 Jeon CH, Chai JY, Seo YI, Jun JB, Koh EM, Lee SK. ; pulmonary hypertension study group of Korean College of Rheumatology. Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. Int J Rheum Dis 2012; 15 (05) e80-e89
  • 140 Dawson JK, Goodson NG, Graham DR, Lynch MP. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000; 39 (12) 1320-1325
  • 141 Gonzalez-Juanatey C, Testa A, Garcia-Castelo A. , et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004; 33 (04) 231-238
  • 142 Davis III JM, Lin G, Oh JK. , et al. Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. Int J Cardiol 2017; 240: 379-385
  • 143 Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 2014; 53 (05) 890-899
  • 144 Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 2014; 66 (04) 803-812
  • 145 Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AMT, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53 (07) 434-439
  • 146 Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41 (03) 262-267
  • 147 Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis 2013; 30 (03) 167-176
  • 148 Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009; 48 (09) 1065-1068
  • 149 Parry SD, Barbatzas C, Peel ET, Barton JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19 (04) 756-764
  • 150 Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C. , et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011; 41 (02) 256-264
  • 151 Mercer LK, Davies R, Galloway JB. , et al; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013; 52 (01) 91-98
  • 152 Khurana R, Wolf R, Berney S, Caldito G, Hayat S, Berney SM. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008; 35 (09) 1704-1708
  • 153 Strangfeld A, Eveslage M, Schneider M. , et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70 (11) 1914-1920
  • 154 Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54 (02) 628-634
  • 155 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol 2016; 35 (10) 2585-2589
  • 156 Singh JA, Saag KG, Bridges Jr SL. , et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68 (01) 1-25
  • 157 Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018; 77 (05) 644-649